Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58


Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology.

Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming DA, Garrido-Laguna I, Grem JL, Hoffe SE, Hubbard J, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen KS, Saltz LB, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gregory KM, Gurski LA.

J Natl Compr Canc Netw. 2019 Sep 1;17(9):1109-1133. doi: 10.6004/jnccn.2019.0043.


Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab.

Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna I.

ESMO Open. 2019 Jul 31;4(4):e000539. doi: 10.1136/esmoopen-2019-000539. eCollection 2019.


Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival.

Lloyd S, Baraghoshi D, Tao R, Garrido-Laguna I, Gilcrease GW 3rd, Whisenant J, Weis JR, Scaife C, Pickron TB, Huang LC, Monroe MM, Abdelaziz S, Fraser AM, Smith KR, Deshmukh V, Newman M, Rowe KG, Snyder J, Samadder NJ, Hashibe M.

Am J Clin Oncol. 2019 Apr;42(4):355-362. doi: 10.1097/COC.0000000000000529.


First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors.

Garrido-Laguna I, Krop I, Burris HA 3rd, Hamilton E, Braiteh F, Weise AM, Abu-Khalaf M, Werner TL, Pirie-Shepherd S, Zopf CJ, Lakshminarayanan M, Holland JS, Baffa R, Hong DS.

Int J Cancer. 2019 Oct 1;145(7):1798-1808. doi: 10.1002/ijc.32154. Epub 2019 Feb 23.


Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle.

Gajiwala S, Torgeson A, Garrido-Laguna I, Kinsey C, Lloyd S.

J Gastrointest Oncol. 2018 Dec;9(6):1014-1026. doi: 10.21037/jgo.2018.05.16. Review.


Large database utilization in health outcomes research in pancreatic cancer: an update.

Torgeson A, Tao R, Garrido-Laguna I, Willen B, Dursteler A, Lloyd S.

J Gastrointest Oncol. 2018 Dec;9(6):996-1004. doi: 10.21037/jgo.2018.05.15. Review.


Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer.

Weldon Gilcrease G, Stenehjem DD, Wade ML, Weis J, McGregor K, Whisenant J, Boucher KM, Thorne K, Orgain N, Garrido-Laguna I, Sharma S.

Invest New Drugs. 2019 Jun;37(3):482-489. doi: 10.1007/s10637-018-0645-2. Epub 2018 Oct 10.


TIGIT: a novel immunotherapy target moving from bench to bedside.

Solomon BL, Garrido-Laguna I.

Cancer Immunol Immunother. 2018 Nov;67(11):1659-1667. doi: 10.1007/s00262-018-2246-5. Epub 2018 Sep 19. Review.


Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy.

Swords DS, Francis SR, Lloyd S, Garrido-Laguna I, Mulvihill SJ, Gruhl JD, Christensen MC, Stoddard GJ, Firpo MA, Scaife CL.

J Gastrointest Surg. 2019 Jul;23(7):1401-1413. doi: 10.1007/s11605-018-3953-0. Epub 2018 Sep 5.


Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden.

Liang WS, Vergilio JA, Salhia B, Huang HJ, Oki Y, Garrido-Laguna I, Park H, Westin JR, Meric-Bernstam F, Fabrizio D, Miller VA, Stephens PJ, Fanale MA, Ross JS, Janku F.

Oncologist. 2019 Feb;24(2):219-228. doi: 10.1634/theoncologist.2018-0058. Epub 2018 Aug 14.


Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy.

Nevala-Plagemann C, Francis S, Cavalieri C, Tao R, Whisenant J, Glasgow R, Scaife C, Lloyd S, Garrido-Laguna I.

ESMO Open. 2018 Jul 25;3(5):e000386. doi: 10.1136/esmoopen-2018-000386. eCollection 2018.


Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.

Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, Ramanathan RK, Ruggiero JT, Shah MA, Urba S, Uronis HE, Lau MW, Laheru D.

J Clin Oncol. 2018 Aug 20;36(24):2545-2556. doi: 10.1200/JCO.2018.78.9636. Epub 2018 May 23.


NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Apr;16(4):359-369. doi: 10.6004/jnccn.2018.0021.


Upper gastrointestinal malignancies in 2017: current perspectives and future approaches.

Solomon BL, Garrido-Laguna I.

Future Oncol. 2018 Apr;14(10):947-962. doi: 10.2217/fon-2017-0597. Epub 2018 Mar 15. Review.


Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins.

Torgeson A, Garrido-Laguna I, Tao R, Cannon GM, Scaife CL, Lloyd S.

ESMO Open. 2018 Jan 27;3(1):e000282. doi: 10.1136/esmoopen-2017-000282. eCollection 2018.


Chemoradiation Therapy for Unresected Extrahepatic Cholangiocarcinoma: A Propensity Score-Matched Analysis.

Torgeson A, Lloyd S, Boothe D, Cannon G, Garrido-Laguna I, Whisenant J, Lewis M, Kim R, Scaife C, Tao R.

Ann Surg Oncol. 2017 Dec;24(13):4001-4008. doi: 10.1245/s10434-017-6131-9. Epub 2017 Oct 17.


A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.

Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G Jr, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ.

BMC Cancer. 2017 Sep 12;17(1):646. doi: 10.1186/s12885-017-3641-6.


Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma.

Smith-Cohn MA, Gill D, Voorhies BN, Agarwal N, Garrido-Laguna I.

Immunotherapy. 2017 Sep;9(10):797-804. doi: 10.2217/imt-2017-0042.


Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies.

Au TH, Wang K, Stenehjem D, Garrido-Laguna I.

J Gastrointest Oncol. 2017 Jun;8(3):387-404. doi: 10.21037/jgo.2017.01.04. Review.


Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer.

Torgeson A, Lloyd S, Boothe D, Tao R, Whisenant J, Garrido-Laguna I, Cannon GM.

Cancer. 2017 Oct 1;123(19):3816-3824. doi: 10.1002/cncr.30780. Epub 2017 Jun 16.


A 30-Year-Old Man with Three Primary Malignancies: A Case of Constitutional Mismatch Repair Deficiency.

Rengifo-Cam W, Jasperson K, Garrido-Laguna I, Colman H, Scaife C, Samowitz W, Samadder NJ.

ACG Case Rep J. 2017 Mar 1;4:e34. doi: 10.14309/crj.2017.34. eCollection 2017.


Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.

Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F.

Oncotarget. 2016 Oct 11;7(41):67521-67531. doi: 10.18632/oncotarget.11750.


Paraneoplastic opsoclonus associated with squamous cell carcinoma of the tongue.

Wynn D, Merriman J, Patel AB, Hitchcock YJ, Garrido-Laguna I, Renner D, Clardy SL.

Clin Neurol Neurosurg. 2016 Oct;149:11-4. doi: 10.1016/j.clineuro.2016.05.023. Epub 2016 Jul 14. No abstract available.


Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.

Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R.

Mol Cancer Ther. 2016 Apr;15(4):533-47. doi: 10.1158/1535-7163.MCT-15-0643. Epub 2016 Mar 23. Review.


Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer.

Patel SB, Gill D, Garrido-Laguna I.

Onco Targets Ther. 2015 Dec 30;9:75-86. doi: 10.2147/OTT.S68558. eCollection 2016. Review.


N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012.

Garrido-Laguna I, Tometich D, Hu N, Ying J, Geiersbach K, Whisenant J, Wang K, Ross JS, Sharma S.

Oncoscience. 2015 Mar 14;2(3):285-93. eCollection 2015.


Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.

Garrido-Laguna I, Hidalgo M.

Nat Rev Clin Oncol. 2015 Jun;12(6):319-34. doi: 10.1038/nrclinonc.2015.53. Epub 2015 Mar 31. Review.


Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome.

Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V; Pan-Cancer Working Group.

Discov Med. 2015 Feb;19(103):109-16. Review.


Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies.

Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V; Pan-Cancer Working Group.

Discov Med. 2015 Feb;19(103):101-8. Review.


A framework for genomic biomarker actionability and its use in clinical decision making.

Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R.

Oncoscience. 2014 Oct 22;1(10):614-623. eCollection 2014.


Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome.

Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V; Pan-Cancer Working Group.

Discov Med. 2014 Dec;18(101):331-9. Review.


Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome.

Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V; Pan-Cancer Working Group.

Discov Med. 2014 Dec;18(101):323-30. Review.


Response to nab-paclitaxel plus gemcitabine in a patient with primary resistance to FOLFIRINOX.

Reese Z, Patel S, Stenehjem DD, Garrido-Laguna I.

J Gastrointest Cancer. 2014 Dec;45 Suppl 1:278-81. doi: 10.1007/s12029-014-9662-3. No abstract available.


Epidemiology and familial risk of synchronous and metachronous colorectal cancer: a population-based study in Utah.

Samadder NJ, Curtin K, Wong J, Tuohy TM, Mineau GP, Smith KR, Pimentel R, Pappas L, Boucher K, Garrido-Laguna I, Provenzale D, Burt RW.

Clin Gastroenterol Hepatol. 2014 Dec;12(12):2078-84.e1-2. doi: 10.1016/j.cgh.2014.04.017. Epub 2014 Apr 24.


Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.

Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R.

Cancer. 2014 Jul 15;120(14):2164-73. doi: 10.1002/cncr.28701. Epub 2014 Apr 17.


A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer.

Garrido-Laguna I, McGregor KA, Wade M, Weis J, Gilcrease W, Burr L, Soldi R, Jakubowski L, Davidson C, Morrell G, Olpin JD, Boucher K, Jones D, Sharma S.

Invest New Drugs. 2013 Oct;31(5):1257-64. doi: 10.1007/s10637-013-9947-6. Epub 2013 Mar 17.


PIK3CA mutations in advanced cancers: characteristics and outcomes.

Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R.

Oncotarget. 2012 Dec;3(12):1566-75.


KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.

Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R.

PLoS One. 2012;7(5):e38033. doi: 10.1371/journal.pone.0038033. Epub 2012 May 31.


Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience.

Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock R.

Clin Colorectal Cancer. 2012 Dec;11(4):297-303. doi: 10.1016/j.clcc.2012.02.001. Epub 2012 Apr 25.


Ridaforolimus in advanced sarcomas: a leap forward or missed opportunity?

Garrido-Laguna I, Janku F.

J Clin Oncol. 2012 Mar 10;30(8):892-3. doi: 10.1200/JCO.2011.40.6538. Epub 2012 Jan 30. No abstract available.


PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.

Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R.

J Clin Oncol. 2012 Mar 10;30(8):777-82. doi: 10.1200/JCO.2011.36.1196. Epub 2012 Jan 23.


Novel therapeutic targets in non-small cell lung cancer.

Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R.

J Thorac Oncol. 2011 Sep;6(9):1601-12. doi: 10.1097/JTO.0b013e31822944b3. Review.


PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.

Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R.

PLoS One. 2011;6(7):e22769. doi: 10.1371/journal.pone.0022769. Epub 2011 Jul 29.


Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.

Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R.

Cancer. 2012 Mar 1;118(5):1422-8. doi: 10.1002/cncr.26413. Epub 2011 Aug 5.


The inverted pyramid of biomarker-driven trials.

Garrido-Laguna I, Hidalgo M, Kurzrock R.

Nat Rev Clin Oncol. 2011 Aug 2;8(9):562-6. doi: 10.1038/nrclinonc.2011.113. Review.


Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.

Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z, Ottenhof NA, Dadon T, Alvarez H, Fendrich V, Rajeshkumar NV, Matsui W, Brossart P, Hidalgo M, Bannerji R, Maitra A, Nelkin BD.

Cancer Biol Ther. 2011 Oct 1;12(7):598-609. Epub 2011 Oct 1.


Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.

Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma R, Hruban RH, Maitra A, Laheru D, Rubio-Viqueira B, Jimeno A, Hidalgo M.

Clin Cancer Res. 2011 Sep 1;17(17):5793-800. doi: 10.1158/1078-0432.CCR-11-0341. Epub 2011 Jul 8.


A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer.

Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D.

Mol Cancer Ther. 2011 Aug;10(8):1311-6. doi: 10.1158/1535-7163.MCT-11-0233. Epub 2011 Jun 14.


Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.

Janku F, Tsimberidou AM, Wang X, Hong DS, Naing A, Gong J, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock R.

Oncologist. 2011;16(3):327-35. doi: 10.1634/theoncologist.2010-0308. Epub 2011 Feb 21.


PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.

Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R.

Mol Cancer Ther. 2011 Mar;10(3):558-65. doi: 10.1158/1535-7163.MCT-10-0994. Epub 2011 Jan 7.

Supplemental Content

Loading ...
Support Center